{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:36:43Z","timestamp":1772692603181,"version":"3.50.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Crohn\u2019s disease is a debilitating chronic inflammatory disorder of the mammalian gastrointestinal tract. Current interventions using anti-tumour necrosis factor [anti-TNF] biologics show long-term benefit in only half of patients. This study focused on the role of the TNF receptor 1 [TNFR1] in pathogenesis in a TNF-driven model of ileitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We studied TNF\u0394AU-rich element [ARE]\/+ [TNFdARE] mice, which develop progressive ileitis similar to Crohn\u2019s ileitis. Histopathological analysis and gene expression profiling were used to characterize disease progression from 5 to 16 weeks. Mice with TNFR1 hemizygosity [TNFdARE\/R1het] allowed us to assess gene dosage effects. Transcriptional profiling established inflection points in disease progression; inflammatory gene expression increased at 8 weeks with a plateau by 10 weeks, so these were selected as endpoints of treatment using the TNF biologic infliximab and the TNFR1-specific XPro1595. Differences in recruitment of cells in the lamina propria were assessed using flow cytometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TNFdARE\/R1het mice displayed stable long-term protection from disease, associated with decreased recruitment of CD11bhiF4\/80lo monocytes and CD11bhiLy6Ghi neutrophils, suggesting an important role of TNFR1 signalling in pathogenesis, and indicating potential benefit from TNFR1-specific intervention. Treatment with infliximab and XPro1595 both showed a similar impact on disease in TNFdARE mice. Importantly, these beneficial effects were greatly surpassed by hemizygosity at the TNFR1 locus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment with either infliximab or XPro1595 produced moderate protection from ileitis in TNFdARE mice. However, hemizygosity at the TNFR1 locus in TNFdARE mice showed far better protection, implicating TNFR1 signalling as a key mediator of TNF-driven disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab222","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T13:15:21Z","timestamp":1639055721000},"page":"978-991","source":"Crossref","is-referenced-by-count":3,"title":["Selective Targeting of Tumour Necrosis Factor Receptor 1 Induces Stable Protection from Crohn\u2019s-Like Ileitis in TNF\u0394ARE Mice"],"prefix":"10.1093","volume":"16","author":[{"given":"Rajrupa","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Division of Biomedical Sciences, School of Medicine, University of California, Riverside School of Medicine , Riverside, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia R","family":"Maltz","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, School of Medicine, University of California, Riverside School of Medicine , Riverside, CA , USA"},{"name":"BREATHE Center, University of California, Riverside , Riverside, CA , USA"},{"name":"Center for Health Disparities Research, University of California, Riverside , Riverside, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Del Castillo","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, School of Medicine, University of California, Riverside School of Medicine , Riverside, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purvi N","family":"Tandel","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, School of Medicine, University of California, Riverside School of Medicine , Riverside, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Messih","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, School of Medicine, University of California, Riverside School of Medicine , Riverside, CA , USA"},{"name":"Department of Evolution, Ecology and Organismal Biology, College of Natural and Agricultural Sciences, University of California, Riverside , Riverside, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Anguiano","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, School of Medicine, University of California, Riverside School of Medicine , Riverside, CA , USA"},{"name":"Department of Chemical and Environmental Engineering, College of Engineering, University of California, Riverside , Riverside, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, School of Medicine, University of California, Riverside School of Medicine , Riverside, CA , USA"},{"name":"BREATHE Center, University of California, Riverside , Riverside, CA , USA"},{"name":"Center for Health Disparities Research, University of California, Riverside , Riverside, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"2022071420375302700_CIT0001","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022071420375302700_CIT0002","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn\u2019s disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"2022071420375302700_CIT0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2022071420375302700_CIT0004","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fimmu.2016.00290","article-title":"Mucosal interactions between genetics, diet, and microbiome in inflammatory bowel disease","volume":"7","author":"Basson","year":"2016","journal-title":"Front Immunol"},{"key":"2022071420375302700_CIT0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.gtc.2017.08.002","article-title":"Complementary and alternative medicine strategies for therapeutic gut microbiota modulation in inflammatory bowel disease and their next-generation approaches","volume":"46","author":"Basson","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"key":"2022071420375302700_CIT0006","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","article-title":"Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease","volume":"34","author":"Murch","year":"1993","journal-title":"Gut"},{"key":"2022071420375302700_CIT0007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/13543784.9.1.103","article-title":"Anti-TNF agents in Crohn\u2019s disease","volume":"9","author":"Van Assche","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"2022071420375302700_CIT0008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"2022071420375302700_CIT0009","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants \u2013 past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022071420375302700_CIT0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","article-title":"Tumor necrosis factor signaling","volume":"10","author":"Wajant","year":"2003","journal-title":"Cell Death Differ"},{"key":"2022071420375302700_CIT0011","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"2022071420375302700_CIT0012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnins.2019.00049","article-title":"Targeting TNFR2 as a novel therapeutic strategy for Alzheimer\u2019s disease","volume":"13","author":"Ort\u00ed-Casa\u00f1","year":"2019","journal-title":"Front Neurosci"},{"key":"2022071420375302700_CIT0013","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1359-6101(02)00019-9","article-title":"Role of TNF\/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments","volume":"13","author":"Kollias","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022071420375302700_CIT0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/eji.201141659","article-title":"TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE","volume":"42","author":"Tsakiri","year":"2012","journal-title":"Eur J Immunol"},{"key":"2022071420375302700_CIT0015","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3390\/ijms19082244","article-title":"Anti-TNF therapy in Crohn\u2019s disease","volume":"19","author":"Adegbola","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2022071420375302700_CIT0016","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1074-7613(00)80038-2","article-title":"Impaired on\/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies","volume":"10","author":"Kontoyiannis","year":"1999","journal-title":"Immunity"},{"key":"2022071420375302700_CIT0017","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.4049\/jimmunol.1102077","article-title":"Convergent and divergent development among M cell lineages in mouse mucosal epithelium","volume":"187","author":"Wang","year":"2011","journal-title":"J Immunol"},{"key":"2022071420375302700_CIT0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1083\/jcb.200902153","article-title":"Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo","volume":"189","author":"Marchiando","year":"2010","journal-title":"J Cell Biol"},{"key":"2022071420375302700_CIT0019","volume-title":"The Interpretation of Ecological Data: A Primer on Classification and Ordination","author":"Pielou","year":"1984"},{"key":"2022071420375302700_CIT0020","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1084\/jem.20020281","article-title":"Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn\u2019s-like inflammatory bowel disease","volume":"196","author":"Kontoyiannis","year":"2002","journal-title":"J Exp Med"},{"key":"2022071420375302700_CIT0021","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1126\/science.1081297","article-title":"Inactivation of TNF signaling by rationally designed dominant-negative TNF variants","volume":"301","author":"Steed","year":"2003","journal-title":"Science"},{"key":"2022071420375302700_CIT0022","doi-asserted-by":"crossref","first-page":"9365","DOI":"10.1523\/JNEUROSCI.1504-06.2006","article-title":"Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson\u2019s disease","volume":"26","author":"McCoy","year":"2006","journal-title":"J Neurosci"},{"key":"2022071420375302700_CIT0023","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1093\/brain\/awr199","article-title":"Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination","volume":"134","author":"Brambilla","year":"2011","journal-title":"Brain"},{"key":"2022071420375302700_CIT0024","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JPD-140410","article-title":"Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro\u00ae1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats","volume":"4","author":"Barnum","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"2022071420375302700_CIT0025","first-page":"CD003574","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn\u2019s disease","author":"Akobeng","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2022071420375302700_CIT0026","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"key":"2022071420375302700_CIT0027","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"2022071420375302700_CIT0028","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"2022071420375302700_CIT0029","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.cell.2015.10.072","article-title":"Epithelial IL-18 equilibrium controls barrier function in colitis","volume":"163","author":"Nowarski","year":"2015","journal-title":"Cell"},{"key":"2022071420375302700_CIT0030","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/mi.2015.13","article-title":"Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3+ Treg cell function in the intestine","volume":"8","author":"Harrison","year":"2015","journal-title":"Mucosal Immunol"},{"key":"2022071420375302700_CIT0031","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1128\/IAI.70.6.3053-3060.2002","article-title":"Characterization of the mouse beta defensin 1, Defb1, mutant mouse model","volume":"70","author":"Morrison","year":"2002","journal-title":"Infect Immun"},{"key":"2022071420375302700_CIT0032","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","article-title":"Adalimumab induces deep remission in patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420375302700_CIT0033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11894-013-0315-7","article-title":"Deep remission in inflammatory bowel disease: looking beyond symptoms","volume":"15","author":"Zallot","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"2022071420375302700_CIT0034","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.crohns.2012.10.018","article-title":"Achievement of deep remission during scheduled maintenance therapy with TNF","volume":"7","author":"Molander","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022071420375302700_CIT0035","doi-asserted-by":"crossref","first-page":"2040622319899297","DOI":"10.1177\/2040622319899297","article-title":"Emerging treatments for inflammatory bowel disease","volume":"11","author":"Hazel","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"2022071420375302700_CIT0036","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"2022071420375302700_CIT0037","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn\u2019s disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420375302700_CIT0038","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/MIB.0000000000000380","article-title":"Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases","volume":"21","author":"Yarur","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2022071420375302700_CIT0039","doi-asserted-by":"crossref","first-page":"e1006261","DOI":"10.1371\/journal.ppat.1006261","article-title":"Ubiquitously expressed Human Beta Defensin 1 (hBD1) forms bacteria-entrapping nets in a redox dependent mode of action","volume":"13","author":"Raschig","year":"2017","journal-title":"PLoS Pathog"},{"key":"2022071420375302700_CIT0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/00365520701682615","article-title":"Association of beta-defensin 1 single nucleotide polymorphisms with Crohn\u2019s disease","volume":"43","author":"Kocsis","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"2022071420375302700_CIT0041","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ng.175","article-title":"Genome-wide association defines more than 30 distinct susceptibility loci for Crohn\u2019s disease","volume":"40","author":"Barrett","year":"2008","journal-title":"Nat Genet"},{"key":"2022071420375302700_CIT0042","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/ng.489","article-title":"Common variants at five new loci associated with early-onset inflammatory bowel disease","volume":"41","author":"Imielinski","year":"2009","journal-title":"Nat Genet"},{"key":"2022071420375302700_CIT0043","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.4049\/jimmunol.1302727","article-title":"The IL18RAP region disease polymorphism decreases IL-18RAP\/IL-18R1\/IL-1R1 expression and signaling through innate receptor-initiated pathways","volume":"192","author":"Hedl","year":"2014","journal-title":"J Immunol"},{"key":"2022071420375302700_CIT0044","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1053\/j.gastro.2015.06.004","article-title":"Tumor necrosis factor receptor 2 restricts the pathogenicity of CD8(+) T cells in mice with colitis","volume":"149","author":"Punit","year":"2015","journal-title":"Gastroenterology"},{"key":"2022071420375302700_CIT0045","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.4049\/jimmunol.1202659","article-title":"TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment","volume":"190","author":"Chen","year":"2013","journal-title":"J Immunol"},{"key":"2022071420375302700_CIT0046","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41419-018-1266-6","article-title":"Differential roles of TNF","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis"},{"key":"2022071420375302700_CIT0047","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.4049\/jimmunol.0903987","article-title":"An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation","volume":"184","author":"Platt","year":"2010","journal-title":"J Immunol"},{"key":"2022071420375302700_CIT0048","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.immuni.2012.08.026","article-title":"Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells","volume":"37","author":"Zigmond","year":"2012","journal-title":"Immunity"},{"key":"2022071420375302700_CIT0049","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gut.33.9.1214","article-title":"Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation","volume":"33","author":"Cappello","year":"1992","journal-title":"Gut"},{"key":"2022071420375302700_CIT0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.gastro.2005.05.013","article-title":"Characteristics of intestinal dendritic cells in inflammatory bowel diseases","volume":"129","author":"Hart","year":"2005","journal-title":"Gastroenterology"},{"key":"2022071420375302700_CIT0051","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/gut.2004.063008","article-title":"Increased number of mature dendritic cells in Crohn\u2019s disease: evidence for a chemokine mediated retention mechanism","volume":"55","author":"Middel","year":"2006","journal-title":"Gut"},{"key":"2022071420375302700_CIT0052","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.3389\/fimmu.2018.02764","article-title":"Dynamics of colon monocyte and macrophage activation during colitis","volume":"9","author":"Jones","year":"2018","journal-title":"Front Immunol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab222\/42097247\/jjab222.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/6\/978\/44890443\/jjab222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/6\/978\/44890443\/jjab222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T20:38:44Z","timestamp":1657831124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/6\/978\/6459321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab222","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,12,10]]}}}